Background
miRNA and prostate cancer
miRNAs as oncogenes and tumor suppressors
miRNAs in prostate cancer
Author year (reference) | Tissue/serum | Outcome | miRNA identified |
---|---|---|---|
Risk/Diagnostic | |||
Ozen, 2008 [79] | Tissue | Risk/Diagnostic | Let-7b-g, 26a-b, 29a-c, 30a-e, 99a-b, 125a-b |
Gandellini, 2009 [78] | Tissue | Risk/Diagnostic | miR-205 |
Mahn 2011 [118] | Tissue/Serum | Diagnostic | let7i, 16, 26a, 195 |
Wach, 2012 [10] | Tissue | Diagnostic | miR-143, 145, 375 |
Avgeris, 2013 [101] | Tissue | Diagnostic | miR-145 |
Srivastava, 2013 [105] | Tissue/Urine | Diagnostic | miR-205, 221, 99b |
Tsuchiyama, 2013 [106] | Tissue | Diagnostic | miR-182-5p |
Guzel 2015 [107] | Tissue | Diagnostic | miR-361-3p, 133b, 221, 203 |
Roberts, 2015 [128] | Tissue/Serum | Diagnostic | miR-200b, 200c, 375 |
Kristensen 2016 [112] | Tissue | Diagnostic | Up: miR-375, 663b, 615-3p, 425-5p, 663a, 182-5p, 183-5p. Down: miR-205-5p, 221-3p, 222-3p, 376c-3p, 136-5p, 455-3p, 455-5p, −154-5p |
Mitchell, 2008 [35] | Serum | Diagnostic | miR-141 |
Lodes, 2009 [137] | Serum | Diagnostic | miR-16, 92a, 103, 107 |
Moltzahn, 2011 [99] | Serum | Diagnostic | miR-26b, 223, 874, 1274a |
Yaman Agaoglu, 2011 [54] | Plasma | Diagnostic | miR-21, 141, 221 |
Selth, 2012 [114] | Serum | Diagnostic | miR-141, 298, 346, 375 |
Chen 2012 [119] | Plasma | Diagnostic | let7c, let7e, 30c, 622, 1285 |
Cheng, 2013 [120] | Serum | Diagnostic | miR-210 |
Haldrup, 2014 [113] | Serum | Diagnostic | miR-141, 375 |
Westermann, 2014 [121] | Serum | Diagnostic | miR-141 |
Kachakova, 2015 [122] | Plasma | Diagnostic | let-7c, 375 |
Haj-Ahmad, 2014 [126] | Urine | Diagnostic | miR-182-5, 484 |
Korzeniewski, 2014 [127] | Urine | Diagnostic | miR-483-5p, 1275, 1290 |
Risk/Progression | |||
Porkka, 2007 [87] | Tissue | Risk/Progression | Let-7a-d, Let-7f, 19b, 145, 184, 198, 202, 210, |
Ambs, 2008 [40] | Tissue | Risk/Progression | miR-1, 32, 101, 106b, 182, 200a, 200b, 494, 520 h |
Mercatelli, 2008 [42] | Tissue | Progression | miR-221, 222 |
Prueitt, 2008 [80] | Tissue | Progression | miR-2, 10, 125b, 224 |
Tong, 2009 [76] | Tissue | Risk/Progression | miR-23b, 100, 135b, 145, 194, 221, 222 |
Wang, 2009 [90] | Tissue | Progression | miR-9*, 16, 221, 222, 331-3p, 145, 551a |
Szczyrba, 2010 [61] | Tissue | Progression | miR-143 |
Shaefer, 2010 [81] | Tissue | Risk/Progression | miR-96, 205 |
Pesta, 2010 [93] | Tissue | Progression | miR-20a |
Khan, 2010 [88] | Tissue | Progression | miR-128 |
Spahn, 2010 [91] | Tissue | Progression | miR-221 |
Hagman, 2010 [92] | Tissue | Risk/Progression | miR-34c |
Brase, 2011 [115] | Tissue/Serum | Progression | miR-141, 375 |
Barnabas, 2011 [103] | Tissue | Progression | miR-151 |
Leite, 2011 [138] | Tissue | Progression | let7c, miR-100, miR-145, miR-191 |
Martens-Uzunova, 2012 [48] | Tissue | Progression | miR-1, 133a, 133b, 143, 143*, 145, 145*, 204, 221, 222 |
Li, 2012 [55] | Tissue | Progression | miR-21 |
Tsuchiyama, 2013 [106] | Tissue | Progression | miR-182-5p |
Amankwah, 2013 [102] | Tissue | Progression | miR-21 |
He, 2013 [134] | Tissue | Progression | miR-19a, miR-374b |
Kristensen, 2014 [89] | Tissue | Progression | miR-224, 452 |
Wang, 2014 [124] | Tissue/Serum | Progression | miR-19, miR-345, miR-519c-5p |
Dip, 2015 [139] | Tissue | Progression | Let-7c |
Zhang, 2011 [100] | Serum | Progression | miR-21 |
Yaman Agaoglu, 2011 [54] | Plasma | Progression | miR-21, miR-221 |
Shen, 2012 [56] | Plasma | Progression | miR-20a, miR-21, miR-145, miR-221 |
Watahiki, 2013 [123] | Plasma | Progression | miR-21, −126, −141, −151-3p, −152, −200c,-375, −423-3p |
Nguyen, 2013 [116] | Serum | Progression | miR-141, miR-375, miR-378, miR-409-3p |
Diagnostic/Progression | |||
Hao, 2011 [95] | Tissue | Diagnostic/Progression | miR-21 |
Mihelich, 2011 [98] | Tissue | Diagnostic/Progression | miR-96, miR-182, miR-183 |
Bryant 2012 [117] | Serum/Urine | Diagnostic/Progression | miR-181a-2, miR-625, miR-107, miR-574-3p, miR-20a, miR-23a, miR-624 |
Mavridis, 2013 [109] | Tissue | Diagnostic/Progression | miR-224 |
Larne, 2013 [108] | Tissue | Diagnostic/Progression | miR-96-5p, miR-183-5p, miR-145-5p, miR-221-5p |
Walter, 2013 [110] | Tissue | Diagnostic/Progression | Up: miR-122, miR-335, miR-184, miR-193, miR-34, miR-138, Down: miR-373, −9, −198, −144 -215, −96, −222, −148, −92, −27, −125, −126, −27 |
Casanova-Salas, 2014 [111] | Tissue/Serum | Diagnostic/Progression | miR-187 and miR-182 |
Mihelich, 2015 [125] | Serum | Diagnostic/Progression | let-7a, −24, −26b, −30c, −93, −100, −103, −106a, −107, −130b, −146a, −223, −451, −874, |
Kristensen, 2016 [112] | Tissue | Diagnostic/Progression | miR185-5p, miR-221-3p, miR-326 |
Treatment response | |||
He, 2013 [134] | Tissue | Treatment Response | miR-23b, miR-220, miR-221, miR-222, and miR-205 |
Lichner, 2013 [135] | Tissue | Treatment Response | miR-152 |
Gonzales, 2011 [133] | Plasma | Treatment Response | miR-141 |
Cheng, 2013 [120] | Serum | Treatment Response | miR-210 |
Someya, 2015 [136] | Blood | Treatment Response | miR-99a |
miRNA investigated | Expression | Tissue | Reference |
---|---|---|---|
let-7a-2,let-7i,16-1,17-5p,20a,21,24-1,25,27a,29a,29b-2,30c,32, 34a,92-2,93-1,95,101-1, 106a, 124a-1,126a-1,135-2,146,149, 181b-1,184,187,191,196-1 197,199a-1, 214,128a, 195,198, 199a-1,199a-2,203,206,214,218-2,223, | up | tumor | Volina, 2006 [45] |
202,210,296,320,370,373*,498,503 | up | tumor | Porkka, 2007 [87] |
let-7i,25,26a-1/2,31,32,34b,92-1/2,93,99b,106b,125a,181a-1/2,182,188,194-1/2,196a/2,200c, 370, 375,425,449 | up | tumor | Ambs, 2008 [40] |
221,222 | up | tumor | Mercatelli, 2008 [42] |
16,19b,24,100,125b,141,143,296 | up | serum | Mitchell, 2008 [35] |
141,200b, 200c | up | prostate cells | Mitchell, 2008 [35] |
221 | up | PCa cells | Mercatelli, 2008 [42] |
221 | up | tumor | Spahn, 2009 [91] |
9*,15a,16,145,221,222,331,551a | up | PCa cells | Wang, 2009 [90] |
128 | up | PCa cells | Khan, 2010 [88] |
let-7a,let-7c,let-7f,15b,20a,21,25,26b,30b,106a, 106b, 126*,148a,200c,218,375, | up | tumor | Szczyrba, 2010 [61] |
25,93,106b | up | tumor | Poliseno, 2010 [61] |
96,182,182*,183 | up | tumor | Schaefer, 2010 [81] |
141 | up | plasma | Gonzales, 2011 [133] |
182 | up | Prostate cells | Mihelich, 2011 [98] |
100,145,191,let7c | up | tumor | Leite, 2011 [138] |
9*,141,200b,375,516a-3p | up | serum | Brase, 2011 [115] |
21 | up | plasma | Yaman Agaoglu, 2011 [54] |
34c | up | PCa cells | Hao, 2011 [95] |
20a,21,221 | up | plasma | Shen, 2012 [56] |
107,141,301a,326,432,484,574-3p,625*,2110 | up | plasma | Bryant, 2012 [117] |
21 | up | tumor | Li, 2012 [55] |
let-7b,7,9*,17,19b,20a,21,25,30d,32,92a-1*,93,95,96,106a*,106b, 106b*,130b,142-3p,141*, 148a, 153,182,182*,183,183*,200b*, 200c*, 210,301b,363,375,425,512-3p,583,615-3p,663,801, | up | tumor | Martens-Uzunova, 2012 [48] |
let-7a,20a,21,106a,106b,375, | up | tumor | Wach, 2012 [10] |
96,124,141,302b,375,378*,489,520d-5p,548a-3p,548c-3p, 875-5p,892b, | up | serum | Nguyen, 2013 [116] |
96-5p,183-3p,183-5p | up | tumor | Larne, 2013 [108] |
10b,15a,15b,16,18a,18b,20b,25,30c,32,34a,34c-5p, 92a, 122, 124,125a-5p,125b,128a,133b, 134, 135b,146b-5p,148b,181a,181b,181c,184,193a-5p,193b,206,214, 215,301a,372 | up | tumor | Walter, 2013 [110] |
19a,188-5p,574-5p,663,939,1224-5p,1225-5p,1249,1915,K12-3,UL70-3p, | up | tumor | He, 2013 [134] |
21 | up | tumor | Amankwah, 2013 [102] |
32,106b-25,375 | up | tumor | Hudson, 2013 [53] |
96-5p,182-5p,183-5p, | up | tumor | Tsuchiyama, 2013 [106] |
141,200a,200c,210,375 | up | serum | Cheng, 2013 [120] |
19a,19b,20a,20b,26a,26b,29c,106a,125a,125b,135a, 141, 148a,151–5p,174b,193a, 196b, 331-3p,365, 374a, 374b, 1274b, | up | tumor | Lichner, 2013 [135] |
19b | up | tumor | Wang, 2014 [124] |
182,SNORD78,U17b,U78_s,U78_x | up | tumor | Casanova-Salas 2014 [111] |
17*,200b*,210,297,375,501-3p,551b,562 | up | serum | Haldrup, 2014 [113] |
345,519c-5p | up | serum | Wang, 2014 [124] |
93,106b-25 | up | PCa cells | Liang, 2014 [61] |
Let-7a,103,107,130b,106a,26b,451,223,93,24,30c,874,100, 146a | up | serum | Mihelich, 2015 [125] |
let-7a-5p,let-7d-3p,let-7d-5p,7-5p,7b-5p,20a-5p,21-3p,25-3p, 29b-2-5p,30d-3p,92a-3p, 92b-3p, 93-3p,96-5p,103a-3p,107, 130b-3p, 182-5p,183-5p,191-5p,196b-5p,200b-3p, 200b-5p, 200c-3p 329, 331-3p,339-3p,342-5p,375,421,423-3p,423-5p, 425-5p, 484, 615-3p,663a,663b,664a-3p, 1248,1260a | up | tumor | Kristensen, 2016 [112] |
Let-7a,let-7b,let-7c,let-7d,let-7 g,16,23a,23b,26a,92,99a,103,125a,125b,143,145,195,199a, 199a*,221,222,497 | down | tumor | Porkka, 2007 [87] |
let-7b,1-2,34a,145,7-1/2,126,128a,133a-1,145,205,218-2,220,221,329,340,345,410, 487,490,494,499,520 h | down | tumor | Ambs, 2008 [40] |
let-7b-g, 26a-b,29a-c,30a-e,99a-b,125a-b,145, 200a-b | down | tumor | Ozen, 2008 [79] |
22,24,27a,27b,29a,30e,101,125a-5p,125b,143, 145, 152, 199a-5p,221,223,320,424, | down | tumor | Szczyrba, 2010 [61] |
16,31,125b,145,149,181b,184,205,221,222 | down | tumor | Schaefer, 2010 [81] |
34c | down | tumor | Hagman, 2010 [92] |
34c | down | PCa cells | Hao, 2011 [95] |
30c,100,223,346 | down | Prostate cells | Mihelich, 2011 [98] |
141 | down | plasma | Yaman Agaoglu, 2011 [54] |
143,145,221 | down | tumor | Wach, 2012 [10] |
1,15a,16-1,133a | down | tumor | Kojima, 2012 [52] |
1,10b,27b,29a,29b,34b,126,126*,130a,133a,133b,139-5p,142-3p,142-5p,143,143*,145,145*, 146a,149,150,155,181b,193b,193b*,204,205,221,221*,222,223,224,328,338-3p, 342-5p, 361-3p 378,378*,455-3p,455-5p,483-3p,485-3p,551b | down | tumor | Martens-Uzunova, 2012 [48] |
181a-2* | down | plasma | Bryant, 2012 [117] |
31-5p,34c-5p,205-5p,221-3p,222-3p | down | tumor | Tsuchiyama, 2013 [106] |
101 | down | tumor | Hudson, 2013 [49] |
221,222 | down | tumor | Amankwah, 2013 [102] |
23b,26b,30c,155,181d,193a-5p,200b-5p,205,221,221-5p,222,224,335,374a,374b, 455-3p,505 | down | tumor | He, 2013 [134] |
145-5p,205-5p,221-5p,409-5p | down | tumor | Larne, 2013 [108] |
224 | down | tumor | Mavridis, 2013 [109] |
222 | down | serum | Cheng, 2013 [120] |
409-3p,623, | down | serum | Nguyen, 2013 [116] |
19a,19b | down | serum | Wang, 2014 [124] |
34a*,34c-3p,187,221*,221,224, | down | tumor | Casanova-Salas 2014 [111] |
1,133b | down | tumor | Karatas, 2014 [55] |
1 | down | Prostate cells | Chang, 2015 [46] |
15a-5p,16-5p,19b-3p,22-3p,23a-3p,23b-3p,24-3p,26a-5p, 27a-3p, 27b-3p,29a-3p, 29b-3p,30a-3p,30a-5p,30c-5p,30e-3p, 30e-5p, 33a-5p,34a-5p,99a-3p,99a-5p,101-3p, 125b-2-3p, 125b-5p, 127-3p,130a-3p,132-3p,136-5p,143-3p,149-5p, 152, 154-5p,155-5p, 181a-5p,181b-5p,195-5p, 199a-3p,199a-5p, 199b-5p,205-5p, 214-5p,218-5p,221-3p,222-3p, 223-3p,335-5p,338-3p,362-3p,363-3p376a-3p,376c-3p,424-5p, 451a,455-3p, 455-5p,497-5p,502-3p,660-5p | down | tumor | Kristensen, 2016 [112] |